Brett Dabruzzo

Weitere Beteiligungen

• 09.12.2022

  15:45 – 15:50 3 Min. 2 Min.

  • ePoster
  • P141

  Safety and tolerability of atogepant: a post hoc analysis of pooled data from four clinical trials

   Migraine
• 09.12.2022

  15:45 – 15:50 3 Min. 2 Min.

  • ePoster
  • P105

  Sustained Response to Atogepant in Individuals with Episodic Migraine: Post Hoc Analyses of 12- and 52-Week Phase 3 Trials

   Migraine
• 09.12.2022

  15:50 – 15:55 3 Min. 2 Min.

  • ePoster
  • P124

  Characterizing gaps in preventive treatment of migraine: global results from the CaMEO-International study

   Migraine
• 09.12.2022

  15:50 – 15:55 3 Min. 2 Min.

  • ePoster
  • P106

  Post-hoc Analysis Evaluating Safety of Atogepant in ADVANCE & Open-Label Extension Participants with Cardiovascular Risk Factors

   Migraine
• 09.12.2022

  16:10 – 16:15 3 Min. 2 Min.

  • ePoster
  • P110

  Subsequent Response to Atogepant in Individuals with Episodic Migraine after an Initial Inadequate Response: Post Hoc Analysis of a 12-week Phase 3 Trial

   Migraine
• 09.12.2022

  16:55 – 17:00 3 Min. 2 Min.

  • ePoster
  • P120

  Monthly Migraine Days, Acute Medication Use Days, and Migraine-Specific Quality of Life in Responders to Atogepant: A Post Hoc Analysis

   Migraine